# A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

> **NCT06628947** · PHASE2 · RECRUITING · sponsor: **Kiora Pharmaceuticals, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **OTHER:** Placebo (Sterile Saline or Balanced Salt Solution)
- **DRUG:** 100 μg KIO-301
- **DRUG:** 50 μg KIO-301

## Key facts

- **NCT ID:** NCT06628947
- **Lead sponsor:** Kiora Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-29
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06628947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06628947, "A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06628947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*